Literature DB >> 12963190

Quality of intraoperative autologous blood withdrawal used for retransfusion after cardiopulmonary bypass.

Hanne I Flom-Halvorsen1, Eivind Øvrum, Rolf Øystese, Frank Brosstad.   

Abstract

BACKGROUND: Intraoperative autologous blood withdrawal protects the pooled blood from the deleterious effects of cardiopulmonary bypass. Following reinfusion after cardiopulmonary bypass, the fresh autologous blood contributes to less coagulation abnormalities and reduces postoperative bleeding and the need for allogeneic blood products. However, few data have been available concerning the quality and potential activation of fresh blood stored at room temperature in the operating room.
METHODS: Forty coronary artery bypass grafting patients undergoing a consistent intraoperative and postoperative autotransfusion protocol had a median of 1,000 mL of autologous blood withdrawn before cardiopulmonary bypass. After heparinization the blood was drained from the venous catheter via venous cannula into standard blood bags and stored in the operating room until termination of cardiopulmonary bypass. Samples for hemostatic and inflammatory markers were taken from the pooled blood immediately before it was returned to the patient.
RESULTS: There was some activation of platelets in the stored autologous blood, as measured by an increase of beta-thromboglobulin. Indications of thrombin formation, as assessed by plasma levels of thrombin-antithrombin complex and prothrombin fragment 1.2 were not seen, and there was no fibrinolytic activity. The red blood cells remained intact, indicated by the absence of plasma free hemoglobin. As for the inflammatory response, the levels of the terminal complement complex remained stable, and the cytokines tumor necrosis factor-alpha and interleukin 6 levels were not increased during storage. The complement activation products increased minimally, but remained within normal ranges.
CONCLUSIONS: Except for slight activation of platelets, there was no indication of coagulation, hemolysis, fibrinolysis, or immunologic activity in the autologous blood after approximately 1 hour of operating room storage. The autologous blood was preserved in a condition of high quality, and retransfusion after cardiopulmonary bypass represents an uncomplicated and almost costless procedure for blood conservation.

Entities:  

Mesh:

Year:  2003        PMID: 12963190     DOI: 10.1016/s0003-4975(03)00349-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Laboratory characteristics and clinical utility of post-operative cell salvage: washed or unwashed blood transfusion?

Authors:  Manuel Muñoz; Robert Slappendel; Dafydd Thomas
Journal:  Blood Transfus       Date:  2010-09-14       Impact factor: 3.443

2.  The effect of hypoxemic resuscitation from hemorrhagic shock on blood pressure restoration and on oxidative and inflammatory responses.

Authors:  Emmanuel E Douzinas; Olga Livaditi; Ilias Andrianakis; Panagiotis Prigouris; Pantelis Paneris; Vassiliki Villiotou; Alex P Betrosian
Journal:  Intensive Care Med       Date:  2007-12-01       Impact factor: 17.440

3.  Anesthetic management for ascending aorta replacement in a patient who refused autologous transfusion for religious reasons.

Authors:  Shinju Obara; Masayuki Nakagawa; Shinichiro Takahashi; Masahiko Akatu; Tsuyoshi Isosu; Masahiro Murakawa
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

4.  Platelet function in stored heparinised autologous blood is not superior to in patient platelet function during routine cardiopulmonary bypass.

Authors:  Rolf C G Gallandat Huet; Adrianus J de Vries; Vladimir Cernak; Ton Lisman
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

5.  Effect of Autotransfusion Using Intraoperative Predonated Autologous Blood on Coagulopathy during Thoracic Aortic Surgery: A Randomized Controlled Trial.

Authors:  Ryo Suzuki; Akihito Mikamo; Yuutaro Matsuno; Akira Fujita; Hiroshi Kurazumi; Atsuo Yamashita; Kimikazu Hamano
Journal:  Ann Thorac Cardiovasc Surg       Date:  2019-07-24       Impact factor: 1.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.